Clinical Trials Logo

Adverse Reaction to Oxytocin clinical trials

View clinical trials related to Adverse Reaction to Oxytocin.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02722356 Completed - Clinical trials for Complications; Cesarean Section

Outcomes After the Implementation of a New Oxytocin Protocol

Start date: April 2016
Phase: N/A
Study type: Interventional

The proposed study is a prospective, randomized, active control, open label study. One hundred sixty subjects undergoing elective cesarean section will be randomly assigned to one of two groups (n = 80 per group): the oxytocin protocol group or the standard practice group. The oxytocin protocol group will receive oxytocin boluses along with a regulated infusion according to a stepwise algorithm following delivery of the placenta. The standard practice group will receive oxytocin via a free flowing ("wide-open") infusion with a concentration of 30 IU per 500 mL of 0.9% normal saline following the delivery of the placenta. Primary outcomes include uterine tone (adequate or inadequate) as assessed by the surgeon, amount of time required to establish adequate uterine tone following the delivery of the infant, total dose of oxytocin required to establish adequate uterine tone, and total calculated blood loss based on pre-operative and post-operative hematocrit concentrations. Secondary outcomes include total estimated blood loss as agreed upon by the surgeon and the anesthesia provider, use of additional uterotonic drugs, mean arterial pressure, and incidence of oxytocin side effects (nausea, chest tightness/pain, and ST-segment changes).

NCT ID: NCT02553226 Completed - Clinical trials for Adverse Reaction to Oxytocin

Continued Versus Discontinued Oxytocin Stimulation of Labour

CONDISOX
Start date: April 2016
Phase: Phase 4
Study type: Interventional

Background: The proposed study will investigate the effect of Syntocinon® (synthetic oxytocin) to induce labour. The hypothesis to be studied is that once the active phase of labour has commenced, Syntocinon® can be discontinued and the labour process will continue. Design: Double-blind randomised controlled multicentre trial Setting: Aarhus University Hospital, Denmark and Regional Hospital of Randers, Denmark Population: 1200 women (600 in each group) stimulated in the latent phase of labour with oxytocin for induction Methods: The Syntocinon® infusion will be replaced with either continuous isotonic saline (placebo) or Syntocinon® infusion (control group), when the active phase of labour is reached. Main outcome measures: Caesarean section (primary outcome), tachysystole, neonatal asphyxia, birth experience Perspective: Syntocinon® is on the list high-alert medications and associated with complications for mother and child during labour. Reducing the duration of stimulation during labour may lower the number of asphyxial sequelae and the number of caesarean sections.